Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Treatment reality and outcome data of patients with advanced papillary cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Goebell, P., Müller, L., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P339), 96.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TNK
2017
Systemic palliativ treatment and outcome in later lines in patients with metastatic colorectal cancer – Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK).

Schnell, R., Uhlig, J., Eggers, E., Jänicke, M., Fleitz, A., Wetzel, N., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P587).

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TKK
2017
How much does fatigue, pain and treatment time interfere with daily life of patients with breast cancer? – Data from the MaLife-Project.

Marschner, N., Scholz, H., Behringer, J., Frank, M., Kruggel, L., Jänicke, M., for the TMK Registry Group, 2017.

Oncol Res Treat 40(suppl 3)(V796), 226. doi:10.1159/000479566

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2017
Treatment of patients with multiple myeloma selected for high-dose chemotherapy and autologous stem cell transplantation – Data from the German prospective TLN Registry.

Knauf, W., Abenhardt, W., Tamm, I., Anhuf, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P608), 178.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2017
Treatment sequences in patients with advanced or metastatic pancreatic cancer in German outpatient cancer centers – data from the TPK clinical cohort study.

Hegewisch-Becker, S., Aldaoud, A., Lerchenmüller, C., Scheiner-Sparna, R., Jänicke, M., Hamm, D., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P825), 235.

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2017
Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P.J., Müller, L., Staehler, M., Müller, Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(V420), 114.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TNK
2017
Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study.

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Goebell, 2017.

Oncol Res Treat 40 (suppl 3)(P343), 97–98.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PAZOREAL
2017
German PASS (GS-DE-312-1750) – A prospective non-interventional post-authorization safety study (PASS) of idelalisib in Germany.

Abenhardt, W., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Watzke, S., Hoechstetter, M., Rummel, M., 2017.

Oncol Res Treat 40 (suppl 3)(P524), 139–140.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
IDELA
2017
Application study of the EQ-5D-5L in Oncology: Linking self-reported quality of life of patients with metastatic colorectal cancer to clinical data from a German tumor registry.

Borchert, K., Jacob, C., Wetzel, N., Jänicke, M., Eggers, E., Sauer, A., Marschner, N., Meise, D., Altevers, J., Mittendorf, T., Braun, S., Greiner, W., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ISPOR / Journal: -
TKK
2017
Clinical Comparison of first-line platin chemotherapy regimens in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) using German registry data.

Haas, J., Meise, D., Ogbonnaya, A., Eaddy, M., Daeßler, K., Sandner, R., Binninger, A., Jaenicke, M., Chiabudini, M., Marschner, N., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ISPOR / Journal: -
TLK
2017